newsfilter
← Latest News
GlobeNewswire·

Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer's Disease

- Dosing of adults with early Alzheimer's disease in clinical trial expected H2 2026 - - Comprehensive preclinical program showed compelling pharmacology and safety profile for VY1706 - - VY1706 uses an IV-delivered,